Aprecia, the 3DP Pharmaceutical Company, has named Kathi Rinesmith, R Ph, MS as its new Senior Vice President of Regulatory Affairs, it was reported on Wednesday.
Rinesmith will head the firm's regulatory strategy, objectives, policies, and programmes for the development and marketing of drug products manufactured with ZipDose Technology, the company's three-dimensional printing technology platform.
Rinesmith has over thirty years of pharmaceutical experience. Most recently, Rinesmith held the position of Director of Global Regulatory Affairs and Global Pharmacovigilance at Adare Pharmaceuticals. He has regulatory and pharmacovigilance experience in commercialised Rx, OTC, and dietary supplement products, and has served as senior executive product development and regulatory roles at Camargo Pharmaceutical Services, Prasco Laboratories, Barr Labs, and Duramed Pharmaceuticals.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business